{ "ok": true, "cik": "946644", "ticker": "AIM", "name": "AIM IMMUNOTECH INC.", "filings": [ { "form": "8-K", "filed": "2026-09-14", "items": [ "1.01 Entry into a Material Definitive Agreement", "3.02 Unregistered Sales of Equity Securities", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/946644/000149315226042592/0001493152-26-042592-index.htm" }, { "form": "8-K", "filed": "2026-09-10", "items": [ "1.01 Entry into a Material Definitive Agreement", "3.02 Unregistered Sales of Equity Securities", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/946644/000149315226042196/0001493152-26-042196-index.htm" }, { "form": "8-K", "filed": "2026-09-04", "items": [ "1.01 Entry into a Material Definitive Agreement", "1.02 Termination of a Material Definitive Agreement", "3.02 Unregistered Sales of Equity Securities", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/946644/000149315226041537/0001493152-26-041537-index.htm" }, { "form": "8-K", "filed": "2026-08-11", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/946644/000149315226036996/0001493152-26-036996-index.htm" }, { "form": "8-K", "filed": "2026-08-10", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/946644/000149315226036753/0001493152-26-036753-index.htm" }, { "form": "10-Q", "filed": "2026-08-07", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/946644/000149315226036609/0001493152-26-036609-index.htm" } ], "events12m": 26, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000946644.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=946644" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up AIM IMMUNOTECH INC. ($AIM). Last filing: 8-K (1.01 Entry into a Material Definitive Agreement), 2026-09-14. 26 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 88000, "revenueGrowth1y": -0.48235294117647054, "revenueGrowthPerYear": -0.10146039165803544, "yearsOfData": 5, "operatingMargin": -132.54545454545453, "operatingMarginPrior": -116.30588235294118, "netMargin": -158.61363636363637, "operatingCashFlow": -10957000, "capitalSpending": null, "freeCashFlow": null, "researchAndDevelopment": 3924000, "researchShareOfRevenue": 44.59090909090909, "cash": 2985000, "longTermDebt": 4476000, "longTermDebtChange": 0.5945849661560385, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 135000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 141000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 202000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 170000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 88000 } ], "totalEquity": -9783000, "totalAssets": 5782000, "equityRatio": -1.691975095122795, "returnOnEquity": null, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": { "low": 44311.52136020683, "high": 79566.3208182049, "baseline": 60378.146014725215, "n": 749, "band": "b00" }, "ifPaceHeld": { "low": 44311.52136020683, "high": 79566.3208182049 } }, "edgarette": "🔖 Exposure: revenue $88K (FY2025), total debt $4.5M. Experience: revenue down 48.2% on the year, down 10.1% a year over 4 years; operating margin -13254.5%, down from -11630.6%. Soundness: equity -169.2% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $44K and $80K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A range, not a forecast. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -13254.5% against a -15.8% median; growth -48.2% against 21.4%.", "peers": { "sic": 2836, "sicDescription": "Biological Products, (No Diagnostic Substances)", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2836", "growth": [ 0.2145, 27 ], "opMargin": [ -0.1582, 31 ], "equityRatio": [ 0.5857, 31 ], "returnOnEquity": [ -0.0646, 25 ] }, "summary": "Aim Immunotech (AIM) saw revenue fall 48.2% in FY2025 to $0 million, operating margin -13255% against a -15.8% median for biological products, (no diagnostic substances), equity -169% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
AIM IMMUNOTECH INC. against its own record and its peers
Operating marginPeer median -15.8%-13254.5%Revenue, on the yearPeer median 21.4%-48.2%Equity of assetsPeer median 58.6%-169.2%Gold tick: the median of 31–31 peers with $50M+ revenue in biological products, (no diagnostic substances)
", "chartHorizon": null, "backtest": { "tests": 13, "hits": 2, "rate": 0.15384615384615385, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T14:14:00.941Z", "hash": "bbb0690c473951b3", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Aim Immunotech (AIM) saw revenue fall 48.2% in FY2025 to $0 million, operating margin -13255% against a -15.8% median for biological products, (no diagnostic substances), equity -169% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 88000, "totalDebt": 4476000, "cash": 2985000 }, "experience": { "revenueGrowth1y": -0.48235294117647054, "revenueGrowthPerYear": -0.10146039165803544, "operatingMargin": -132.54545454545453, "operatingMarginPrior": -116.30588235294118, "netMargin": -158.61363636363637, "freeCashFlow": null }, "soundness": { "equityRatio": -1.691975095122795, "returnOnEquity": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2836, "sicDescription": "Biological Products, (No Diagnostic Substances)", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2836", "growth": [ 0.2145, 27 ], "opMargin": [ -0.1582, 31 ], "equityRatio": [ 0.5857, 31 ], "returnOnEquity": [ -0.0646, 25 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": { "low": 44311.52136020683, "high": 79566.3208182049, "baseline": 60378.146014725215, "coverage": 0.8, "method": "v3", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); range = 10th to 90th percentile of how SEC company-years of the same size band actually turned out", "calibratedOn": { "companyYears": 749, "sizeBand": "b00" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 13, "hits": 2, "rate": 0.15384615384615385, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T14:14:00.941Z", "hash": "bbb0690c473951b3", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000946644.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=946644" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }